News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. CPI, University of Michigan sentiment and factory orders are due Friday morning, setting up potential market-moving data.
  • Sodexo reports before the open and The Children's Place reports after the close, with the latter expected to post an EPS loss.
  • Stocks swung sharply Thursday as company-specific news drove outsized moves across mega-, mid- and small-cap names.
  • Texas Pacific Land shares fell sharply after the death of a major shareholder executive raised ownership and leadership concerns.
  • Gulf Coast refining margins surged to multi-year highs as Middle East disruptions tightened fuel markets and boosted U.S. exports.
  • Mexico's annual inflation rose to 4.59% in March, deepening a split at the central bank ahead of the May decision.
  • White House said Trump discussed pulling some U.S. forces from Europe, but no formal decision or Pentagon orders have been issued.

Latest Articles

Morgan Stanley Cuts Lennox International Price Target to $450, Cites Soft Demand and Inventory Risks

Morgan Stanley Cuts Lennox International Price Target to $450, Cites Soft Demand and Inventory Risks

Morgan Stanley reduced its price target on Lennox International to $450 from $475 and kept an Underweight rating following the company’s Q4 2025 results. The firm pointed to ongoing volume softness, weak end-market demand, under-absorption risk and pricing pressure as drivers for the lower valuation. Morgan Stanley’s forecasts for 2026 and Q1 2026 …

Atlanta Fed’s Bostic Advocates Patience on Rates, Flags Inflation Risks

Atlanta Fed’s Bostic Advocates Patience on Rates, Flags Inflation Risks

Atlanta Fed President Raphael Bostic told CNBC that the Federal Reserve should adopt a patient stance on interest rates while remaining alert to inflationary pressures. He said there are "ways to go on inflation," expects tariff impacts to show up in the first half of 2026, and wants clear evidence of a return to 2% inflation before altering policy…

Bernstein Maintains Outperform on UnitedHealth as Medicare Advantage Advance Rates Trigger Sharp Stock Moves

Bernstein Maintains Outperform on UnitedHealth as Medicare Advantage Advance Rates Trigger Sharp Stock Moves

Bernstein SocGen has reaffirmed an Outperform rating and a $405.00 price target on UnitedHealth Group (UNH) after the shares plunged about 20% in the wake of Medicare Advantage advance rate announcements and the company’s fourth-quarter results. Analyst Lance Wilkes outlined five principal investor concerns, and Bernstein adjusted its model to acco…

Bernstein Lifts RTX Price Target to $204, Cites Raytheon Margin Strength

Bernstein Lifts RTX Price Target to $204, Cites Raytheon Margin Strength

Bernstein raised its 12-month price target on RTX Corp. to $204 from $189 while retaining a Market Perform designation, pointing to stronger-than-expected results in the Raytheon segment. RTX recently posted quarterly and full-year beats, a rising backlog at Raytheon and several sizable contract awards, but the firm signaled ongoing concerns around…

Buy the Molina Dip: Buy MOH After CMS 2027 Medicare Shock

Buy the Molina Dip: Buy MOH After CMS 2027 Medicare Shock

Molina Healthcare ($MOH) sold off after CMS proposed a 0.09% Medicare Advantage rate increase for 2027 on 01/27/2026. The pullback creates a mid-term swing entry into a company with a $9.5B market cap, P/E near 11, and deep Medicaid exposure (roughly 75% of revenue). We recommend buying the dip with a clear entry, stop and target and a 45-trading-d…

Lucid Lowers Quince Therapeutics to Sell After Phase 3 NEAT Failure

Lucid Lowers Quince Therapeutics to Sell After Phase 3 NEAT Failure

Lucid Capital Markets downgraded Quince Therapeutics Inc. (QNCX) from Buy to Sell and removed its price target after the company announced that its pivotal Phase 3 NEAT trial failed to meet both primary and key secondary endpoints. The trial miss, the decision to discontinue the program that represented Quince’s sole development asset, and the comp…

Precious and Industrial Metals Retreat as Profit-Taking Follows Record Highs

Precious and Industrial Metals Retreat as Profit-Taking Follows Record Highs

Gold, silver and copper reversed course on Friday as investors moved to lock in gains after a string of record highs. Market participants cited waning expectations for aggressive U.S. interest rate cuts and a firmer dollar following the announcement of Kevin Warsh as the preferred candidate to lead the U.S. Federal Reserve. Thin liquidity and specu…